spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

US lobby group PhRMA plans website to boost access to cheaper drugs

U.S. pharmaceutical lobby group PhRMA said on Monday it would launch a new website in January to help patients buy prescription drugs directly from manufacturers, bypassing pharmacy benefit managers and other middlemen.

The website, to be called AmericasMedicines.com, will allow drugmakers to list medicines available for direct purchase and connect patients with programs that offer lower prices and fewer barriers to access.

The move is part of a broader push by the industry to simplify how Americans get their medicines and reduce out-of-pocket costs following mounting pressure from the Trump administration.

President Donald Trump has urged pharmaceutical companies to bring down U.S. drug prices, and in July sent letters to 17 major companies demanding they slash U.S. prescription drug prices to match those paid in other developed nations.

The companies have until September 29 to respond with binding commitments.
The White House has also floated the idea of a government-run website, possibly named TrumpRx, to help Americans shop for cheaper medicines, Bloomberg News reported earlier this month.

PhRMA did not immediately respond to a request for more details on its upcoming website.
The direct-to-consumer model has recently gained traction, with companies like Eli Lilly (LLY.N), opens new tab, Pfizer (PFE.N), opens new tab, and AstraZeneca (AZN.L), opens new tab launching their own platforms for select drugs.

Earlier on Monday, Novartis (NOVN.S), opens new tab said it would launch a direct-to-patient platform in the U.S., beginning November 1, to sell select units of anti-inflammatory drug Cosentyx at 55% discount off list price to cash-paying patients.

The Swiss drugmaker said it would later expand the platform to include other products, as well as explore the option of a direct-to-employer model for cash-paying patients in the U.S.

The industry group also said drugmakers had announced investments of $500 billion in U.S.-based manufacturing and infrastructure, which are expected to generate $1.2 trillion in economic output and create over 100,000 new jobs.

Hot this week

Daewoong Pharmaceutical Holds Talks with Saudi Officials on Bioindustry Cooperation

Daewoong Pharmaceutical said on October 17 that it met...

Novo Nordisk chair and independent directors to exit in strategy dispute

The chair of Wegovy maker Novo Nordisk and six...

Hologic to go private in up to $18.3 billion deal backed by Blackstone, TPG

Medical diagnostics firm Hologic has agreed to be acquired...

China’s Innovent signs $11.4 billion cancer therapy deal with Japan’s Takeda

-China’s Innovent Biologics said on Wednesday it had signed...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img